Lupin Limited has informed the Exchange regarding a press release dated Jun 03, 2026, titled "Lupin and Natco Receive Approval from U.S. FDA for Eribulin Mesylate Injection".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin, along with partner Natco, has received approval from the U.S. FDA for Eribulin Mesylate Injection. Eribulin is a chemotherapy drug used to treat metastatic breast cancer, and this approval likely pertains to a generic version of Eisai's Halaven. The nod allows Lupin and Natco to manufacture and market the product in the United States. The U.S. market for this drug has been growing, and generic entry could provide meaningful revenue opportunities for Lupin's complex injectables portfolio.
Positive for Lupin — adds another complex injectable product to its U.S. portfolio and strengthens its oncology presence. Short-term stock reaction may be mildly positive, though actual revenue impact depends on launch timing and competition.